Last 1.13 GBp
Change Today +0.025 / 2.27%
Volume 717.2K
VRP On Other Exchanges
As of 11:30 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

1.10 GBp
Previous Close
1.10 GBp
Day High
1.13 GBp
Day Low
1.10 GBp
52 Week High
10/30/13 - 5.64 GBp
52 Week Low
06/23/14 - 1.05 GBp
Market Cap
Average Volume 10 Days
-0.0060 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

10 Employees
Last Reported Date: 07/3/14

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.4K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 42.0K GBP
Compensation as of Fiscal Year 2013.

verona pharma plc (VRP) Key Developments

Verona Pharma plc announces Management Changes

Verona Pharma plc announced that it has appointed Biresh Roy as chief financial officer and member of the board of directors with immediate effect. He takes over from Richard Bungay whose appointment was part-time and a non-board role. During this time he also acted as chief financial officer for several companies, including Enigma diagnostics, Xytis, Morphochem and Santhera.

Verona Pharma plc Reports Unaudited Group Earnings Results for the Six Months Ended June 30, 2014

Verona Pharma plc reported unaudited group earnings results for the six months ended June 30, 2014. For the six months, the company reported operating loss of GBP 1,391,266 compared to GBP 1,308,902 a year ago. Loss before taxation was GBP 1,388,046 compared to GBP 1,307,027 a year ago. Total comprehensive loss for the period was GBP 1,388,046 compared to GBP 1,017,627 a year ago. Loss per ordinary basic and diluted Share was 0.19 pence compared to 0.31 pence a year ago. Net cash outflow from operating activities was GBP 1,469,753 compared to GBP 1,291,199 a year ago. Purchase of plant and equipment was GBP 1,507 compared to GBP 1,197 a year ago. Research and development expenditure, which was expensed as incurred, amounted to GBP 0.87 million compared to GBP 0.80 million in 2013.

Verona Pharma plc to Report First Half, 2014 Results on Sep 11, 2014

Verona Pharma plc announced that they will report first half, 2014 results on Sep 11, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 1.13 GBp +0.025

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at